Victor Malassigné
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Victor Malassigné has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Hélène Péré
Centre de Recherche des Cordeliers 1 Paris, France
6 shared publications - Imane Doghman
Centre de Recherche des Cordeliers 1 Paris, France
6 shared publications - Anne Auperin
Gustave Roussy 4 Biostatistics and Epidemiology Office Inserm U1018 Oncostat, Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France
5 shared publications - Anne-Laure Gaultier
Department of Radiology, European Georges Pompidou Hospital, Paris, France
5 shared publications - Aurelien Marabelle
University of Paris Saclay, Gustave Roussy Cancer Center, Villejuif, France
5 shared publications - Bastien Rance
Hôpital Européen Georges Pompidou
5 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S8 from HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Supplementary Figure S1-S8 from HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S8 from HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Supplementary Figure S1-S8 from HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Definition of viral genomic status groups
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Definition of viral genomic status groups
- 15 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4434-4447
HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Purpose: A subset of patients with human papillomavirus (HPV)–positive oropharyngeal squamous cell carcinoma (OPSCC) develops disease recurrence despite generally favorable outcomes. Reliable biomarkers for risk stratification remain lacking. We investigated whether comprehensive viral genomic profiling refines prognostic classification. Experimental Design: Tumor samples from 100 patients with p16-positive and HPV DNA–positive OPSCC enrolled in 2 independent cohorts were analyzed using targeted viral capture sequencing. Viral genotype, sublineage, single-nucleotide variation, virus–host integration sites, viral structural variants (SV), clonality, and viral copy number were characterized. Associations with cumulative incidence of progression, progression-free survival (PFS), and overall survival were assessed at 60 months. Results: HPV16 was detected in 94 tumors, 83 of which belonged to the HPV16_A1 sublineage. Within this sublineage, 20 tumors harbored strictly episomal viral genomes, whereas 63 exhibited integration and/or viral SV. No progression events occurred in the strictly episomal HPV16_A1 subgroup, whereas 12 occurred among HPV16_A1 tumors with an integration and/or SV. At 60 months, no progression events were observed in strictly episomal HPV16_A1 tumors compared with a 23.1% cumulative incidence of progression in HPV16_A1 tumors with an integration and/or SV. Previously reported high-risk single-nucleotide variants and a novel upstream regulatory region variant were associated with worse PFS. Integration sites were enriched in open chromatin and promoter regions and clustered within viral E2 and E4 genes. Conclusions: Within HPV16_A1 tumors, viral genomic architecture defines clinically distinct subgroups. Strictly episomal (wild-type) genomes identify a low-risk population, whereas integration and SV characterize higher-risk disease.
- 15 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4434-4447
HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Purpose: A subset of patients with human papillomavirus (HPV)–positive oropharyngeal squamous cell carcinoma (OPSCC) develops disease recurrence despite generally favorable outcomes. Reliable biomarkers for risk stratification remain lacking. We investigated whether comprehensive viral genomic profiling refines prognostic classification. Experimental Design: Tumor samples from 100 patients with p16-positive and HPV DNA–positive OPSCC enrolled in 2 independent cohorts were analyzed using targeted viral capture sequencing. Viral genotype, sublineage, single-nucleotide variation, virus–host integration sites, viral structural variants (SV), clonality, and viral copy number were characterized. Associations with cumulative incidence of progression, progression-free survival (PFS), and overall survival were assessed at 60 months. Results: HPV16 was detected in 94 tumors, 83 of which belonged to the HPV16_A1 sublineage. Within this sublineage, 20 tumors harbored strictly episomal viral genomes, whereas 63 exhibited integration and/or viral SV. No progression events occurred in the strictly episomal HPV16_A1 subgroup, whereas 12 occurred among HPV16_A1 tumors with an integration and/or SV. At 60 months, no progression events were observed in strictly episomal HPV16_A1 tumors compared with a 23.1% cumulative incidence of progression in HPV16_A1 tumors with an integration and/or SV. Previously reported high-risk single-nucleotide variants and a novel upstream regulatory region variant were associated with worse PFS. Integration sites were enriched in open chromatin and promoter regions and clustered within viral E2 and E4 genes. Conclusions: Within HPV16_A1 tumors, viral genomic architecture defines clinically distinct subgroups. Strictly episomal (wild-type) genomes identify a low-risk population, whereas integration and SV characterize higher-risk disease.
- 25 November 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (12) , e70720
HPV Genomic Status in Early Cervical Cancer and Its Prognosis Association
Identify specific Human Papilloma Virus (HPV) genomic status by HPV capture technique coupled with next‐generation sequencing (NGS) in patients with early cervical cancer (ECC) regarding 2018 FIGO stages and correlate these statuses with prognosis. HPV sequencing by Capture technique coupled with NGS was performed on 34 tumors samples of ECC patients without histologically sentinel lymph node (SLN) metastasis in a retrospective study. NGS data were analyzed in our in‐house VIROCAPT2 pipeline to determine precise HPV genomic status such as the complete sequence of HPV genome, its integration or not in host genome and correlate this viral identity card with patient's clinical prognosis. As expected, HPV16 remains the most common genotype (60%, n = 21/35) in ECC. HPV integration was identified in 40% ( n = 14/35) of samples. We found that in ECC, integration events were related with HPV genotype ( p = 0.0005). Among the 40% of integrated HPV, 8 were found integrated within human genes, including 2 into oncogenes. Finally, women with integrated HPV had a poorest outcome with a strong correlation between progression‐free survival and HPV integration ( p = 0.0035) and interestingly, the 2 HPV integrated into oncogenes were observed in patients who died from cancer. HPV genomic status seems to be a key prognostic factor in early stage cervical cancer, with HPV integration strongly linked to poor outcomes. Larger studies are needed to confirm the clinical relevance of HPV ID card for risk stratification and treatment decisions.
- 25 November 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (12) , e70720
HPV Genomic Status in Early Cervical Cancer and Its Prognosis Association
Identify specific Human Papilloma Virus (HPV) genomic status by HPV capture technique coupled with next‐generation sequencing (NGS) in patients with early cervical cancer (ECC) regarding 2018 FIGO stages and correlate these statuses with prognosis. HPV sequencing by Capture technique coupled with NGS was performed on 34 tumors samples of ECC patients without histologically sentinel lymph node (SLN) metastasis in a retrospective study. NGS data were analyzed in our in‐house VIROCAPT2 pipeline to determine precise HPV genomic status such as the complete sequence of HPV genome, its integration or not in host genome and correlate this viral identity card with patient's clinical prognosis. As expected, HPV16 remains the most common genotype (60%, n = 21/35) in ECC. HPV integration was identified in 40% ( n = 14/35) of samples. We found that in ECC, integration events were related with HPV genotype ( p = 0.0005). Among the 40% of integrated HPV, 8 were found integrated within human genes, including 2 into oncogenes. Finally, women with integrated HPV had a poorest outcome with a strong correlation between progression‐free survival and HPV integration ( p = 0.0035) and interestingly, the 2 HPV integrated into oncogenes were observed in patients who died from cancer. HPV genomic status seems to be a key prognostic factor in early stage cervical cancer, with HPV integration strongly linked to poor outcomes. Larger studies are needed to confirm the clinical relevance of HPV ID card for risk stratification and treatment decisions.